Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features

Cancer Chemotherapy and Pharmacology

Volumn 78, Issue 2, 2016, Pages 325-332

  Kim, Jwa Hoon ^a   Park, Inkeun ^a,b   Lee, Jae Lyun ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Gachon University College of Medicine   (South Korea)

Author keywords

Pazopanib; Poor risk group; Renal cell carcinoma; Sunitinib

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; HEMOGLOBIN; LACTATE DEHYDROGENASE; PAZOPANIB; SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE;

ABDOMINAL PAIN; ADOLESCENT; ADRENAL METASTASIS; ADULT; ADVANCED CANCER; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BONE METASTASIS; BRAIN METASTASIS; CANCER CONTROL; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; KIDNEY METASTASIS; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAUSEA; NEPHRECTOMY; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PANCREAS METASTASIS; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RASH; RISK ASSESSMENT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; CARCINOMA, RENAL CELL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; KIDNEY NEOPLASMS; METASTASIS; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PYRIMIDINES; PYRROLES; RETROSPECTIVE STUDIES; RISK FACTORS; SULFONAMIDES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84975246700     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-016-3093-8     Document Type: Article

References (19)

1. Janzen NK, Kim HL, Figlin RA, Belldegrun AS (2003) Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin N Am 30(4):843–852
2. Cohen HT, McGovern FJ (2005) Renal-cell carcinoma. N Engl J Med 353(23):2477–2490. doi:10.1056/NEJMra043172
3. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20(1):289–296
4. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271–2281. doi:10.1056/NEJMoa066838
5. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27(34):5794–5799. doi:10.1200/jco.2008.21.4809
6. Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N, Kollmannsberger C, Rini BI, Choueiri TK (2013) External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 14(2):141–148. doi:10.1016/s1470-2045(12)70559-4
7. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124. doi:10.1056/NEJMoa065044
8. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584–3590. doi:10.1200/jco.2008.20.1293
9. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6):1061–1068. doi:10.1200/jco.2009.23.9764
10. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369(8):722–731. doi:10.1056/NEJMoa1303989
11. Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schoffski P, Mainwaring P, Nieto A, Yuan J, Bukowski R (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10(8):757–763. doi:10.1016/s1470-2045(09)70162-7
12. Lee JL, Park I, Park K, Park S, Ahn Y, Ahn JH, Kim TW, Ahn S, Song C, Hong JH, Kim CS, Ahn H (2012) Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features. J Cancer Res Clin Oncol 138(4):687–693. doi:10.1007/s00432-012-1148-8
13. Britten CD, Kabbinavar F, Hecht JR, Bello CL, Li J, Baum C, Slamon D (2008) A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol 61(3):515–524. doi:10.1007/s00280-007-0498-4
14. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (Oxford, England: 1990) 45(2):228–247. doi:10.1016/j.ejca.2008.10.026
15. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet (London, England) 370(9605):2103–2111. doi:10.1016/s0140-6736(07)61904-7
16. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28(13):2137–2143. doi:10.1200/jco.2009.26.5561
17. Yoo C, Kim JE, Lee JL, Ahn JH, Lee DH, Lee JS, Na S, Kim CS, Hong JH, Hong B, Song C, Ahn H (2010) The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn J Clin Oncol 40(10):980–985. doi:10.1093/jjco/hyq073
18. Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Negrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D (2014) Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol 32(14):1412–1418. doi:10.1200/JCO.2013.50.8267
19. Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, Bukowski R (2005) Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23(4):832–841. doi:10.1200/jco.2005.05.179